New drug combo aims to outsmart recurrent ovarian cancer
Disease control
Recruiting now
This trial tests a new experimental drug called CPI-0209 (Tulmimetostat) combined with the chemotherapy drug carboplatin in women whose ovarian cancer has returned but still responds to platinum-based treatments. The study aims to find the safest dose of CPI-0209 when given with …
Phase: PHASE1 • Sponsor: Lan Coffman • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC